San Diego, CA, January 20, 2012 --(PR.com
)-- BioRegenerative Sciences, Inc. (BRS), a privately owned stem cell therapeutics corporation headquartered in San Diego, CA, USA, announced today the signing of a memorandum of understanding (MOU) with Nurture Earth Pvt. Ltd. (NE) of the MIT Campus, Aurangabad, India. The MOU sets the framework for the creation of an India based Joint Venture between BRS and NE, named BioRegenerative Sciences India, for the construction and operation of a facility to produce, register, market, and sell stem cell-based pharmaceutical and therapeutic products. Signing the MOU were Dr Greg Maguire, CEO and Co-Founder of BRS, and Munish Sharma, Managing Director and Co-Founder of NE. BRS’ patent pending technology, called S2RM Technology,TM uses the molecules that multiple stem cell types release to heal the body, producing the most efficacious products on the market. BRS India will help develop, register, and sell these products to markets that they would have been unable to reach without the help of their new joint venture.
During a week long tour of India with a delegation from the MIT-sponsored Forefront Summitt in Mumbai, BRS and NE were able to construct a plan for the JV with the help of key delegates that included: Simon Taylor, J.D. a Harvard-trained lawyer expert in corporate and technology law and mergers and acquisitions who helped form the legal and business structure, Stephan W. Bisenious of Lee County Economic Development Group, Inc. of Iowa who enables USA-Indian business opportunities, Dr. Jag Khalsa of the National Institutes of Health in Bethesda, Maryland, USA who facilitates possible research opportunities for the JV, Sanjay Deshmukh, Co-Founder and Director of Nurture Earth, a business development specialist, Dr. Mithu Pottathil, an expert in intellectual property, and Jeff Sherill of the Rady School of Mangement at UCSD, an expert in strategic business alliances.
Munish Sharma stated that, “This JV is made possible through the cooperation of MIT, NE, BRS, and a number of other Indian technology companies that will work with the JV to develop, manufacture, and bring the products through registration and into the marketplace.” Dr. Greg Maguire added, “Our MIT-sponsored delegation brought all the necessary parts to begin the development of our JV, and BRS looks forward to a close and long working relationship with our new Indian partners to further develop our stem cell-based technology and bring the resulting products to the world-wide market.” Dr. Ravi Pottathil, a former senior scientist at Roche, serial entrepreneur, and Co-Founder and Director of NE pointed out that the JV will benefit India and the USA by advancing BRS’s core S2RM TechnologyTM in facilities both in the USA and India, and eventually bringing approved prescription biologics to both countries. Not only will this JV bring jobs and economic prosperity to both countries, but patient care will be greatly enhanced too. Speaking from the USA, Peter Friedman, President and Co-Founder of BRS added that, “BRS’ products use the molecules that stem cells release to heal the body and are the most efficacious on the market. Our new JV will help develop and sell these products to markets that we would have been unable to reach without the help of our new JV.”